Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.53 |
| ▸ | PGR | P06401 | 4/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221703 | 0.92 | NR3C1 (0.55) | ARNR3C1PGRMAPK8MAPK10 | |
| SCHEMBL4230100 | 0.88 | NR3C1 (0.51) | ARNR3C1PGRMAPK8MAPK10 | |
| SCHEMBL4215115 | 0.85 | NR3C1 (0.50) | NR3C1PGRMAPK8MAPK10SMO | |
| SCHEMBL4217208 | 0.85 | SMO (0.50) | ARNR3C1PGRMAPK8MAPK10 | |
| SCHEMBL4219336 | 0.84 | HPGDS (0.55) | — | |
| SCHEMBL4221389 | 0.84 | NR3C1 (0.54) | ARNR3C1PGRMAPK8MAPK10 | |
| SCHEMBL4221686 | 0.84 | NR3C1 (0.47) | NR3C1PGRMAPK8MAPK10SMO | |
| SCHEMBL4219608 | 0.84 | SMO (0.48) | ARNR3C1PGRMAPK8MAPK10 | |
| SCHEMBL4220428 | 0.82 | HPGDS (0.51) | — | |
| SCHEMBL4219613 | 0.82 | SMO (0.47) | ARNR3C1PGRMAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | AR 4348/4885NR3C1 871/4885PGR 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.